$Repare Therapeutics (RPTX.US)$Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor 5 MINUTES AGO, 7:05 AM EDT VIA BUSINESSWIRE
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more